A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels
A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels. Because cancer treatment regimens are costly, they have been highly affected by the sequester cuts. ACCC Buzz reports:
After a recent hearing by the House Energy and Commerce Health Subcommittee, the Cancer Patient Protection Act of 2013 (HR 1416) is gaining support. The bi-partisan bill was introduced by Congresswoman Renee Ellmers and now enjoys 97 co-sponsors.
Our fight is not over, however. ACCC continues to educate other members of the House about the importance of this legislation. ACCC recently met with Representative Erik Paulsen’s office, who is one of the latest members to sign onto HR 1416. We are continuing to work to identify a champion in the Senate.
Read the full story here: http://bit.ly/15mNCLo
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen